Search academic texts

Information × Registration Number 0225U001207, (0122U002451) , R & D reports Title Individualization of combined treatment of locally advanced cancer of the oral cavity and large salivary glands based on the study of molecular genetic and molecular biological markers of aggressiveness of the disease popup.stage_title Провести статистичний аналіз отриманих результатів за фрагментами дослідження та розробити алгоритм лікування хворих на основі молекулярних маркерів пухлинного прогресування та визначення відповіді пухлини на лікування Head Kravets Oleh V., д.мед.н. Registration Date 27-01-2025 Organization National Cancer Institute popup.description1 Improve the treatment outcomes of patients with oral cancer and large salivary glands by studying molecular markers of tumor progression popup.description2 The object of research: oral cancer and oropharyngeal cancer. The purpose of the proceedings: To identify specific regulatory microRNAs associated with tumor sensitivity to neoadjuvant chemotherapy and to develop an algorithm for individualized treatment of patients with locally advanced oral and oropharyngeal cancer. Research methods - clinical, pathomorphological, immunohistochemical, endoscopic, radiologic, polymerase chain reaction analysis. The association of microRNA-10b and -155 expression levels with lymph node metastasis, tumor differentiation grade, and Ki-67 levels did not differ between the groups of p16INK4a-positive and p16INK4a-negative tumors (p > 0.05), indicating the possibility of using these microRNAs as prognostic markers for oral squamous cell carcinoma independent of p16INK4a status. It was proved that the levels of microRNA-21 and -155 were positively correlated with TNM T (r=0.68 and r=0.75, respectively) (p<0.05) and TNM N (r=0.78 and r=0.71, respectively) (p<0.05). The expression of microRNA-375 was negatively correlated with TNM T (r=-0.67) (p<0.05), and its level was 2.1 times higher in saliva of patients with N1-2 than in saliva of patients with N0 (r=-0.59). Analysis of microRNA-21, microRNA-155, and microRNA-375 in relation to tumor response to neoadjuvant chemotherapy showed that only microRNA-21 (p=0.004) and microRNA-375 (p=0.01) were associated with response to therapy. It was found that the levels of microRNA-21, microRNA-155, and microRNA-375 in saliva in 85% of patients diagnosed with OSCC and OPSCC with tumors resistant to NACT were above 10.1, 9.8, and below 1.1 с.u., respectively, while 85% of patients who responded to NACT had lower levels of microRNA-21 (<9.2 c.u.), -155 (<9.4 c.u.), and higher levels of microRNA-375 (>2.1 c.u.). The research resulted in the development of an algorithm for individualized treatment of patients with locally advanced OSCC and OPSCC based on the identified specific regulatory microRNAs. Product Description popup.authors Burtyn Olha V. Korobko Yevhen V. Cherniienko Viktor V. popup.nrat_date 2025-01-27 Close